business

BofA reiterates Regeneron stock rating after melanoma trial miss

Investing.com · May 18, 2026, 5:51 AM · Also reported by 2 other sources

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Citi Maintains Buy Rating on Netflix (NFLX) Stock Yahoo Finance Robert W. Baird Maintains Hold Rating on Fortinet (FTNT) Stock

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

BofA reiterates Regeneron stock rating after melanoma trial miss

Also covered by

More in business